NCT01690325View on ClinicalTrials.gov

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

DRUG

Trastuzumab

DRUG

Bevacizumab

DRUG

Epirubicin

DRUG

Cyclophosphamid

Trial Locations (1)

81377

Breast Centre, University of Munich, LMU, Munich

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

West German Study Group

OTHER

NCT01690325 - Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) | Biotech Hunter | Biotech Hunter